annual-meeting-preview-prime-oncology

What’s Trending at the ASCO Annual Meeting This Year

The American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held at the McCormick Place Convention Center in Chicago from June 2-6, is fast approaching. According to the organizer, more than 38,000 participants from around the globe are expected to discuss the latest clinical trials updates and new research findings in oncology, state-of-the-art multidisciplinary treatment, and strategies to overcome barriers in cancer care and research. The theme of this year’s meeting, developed by ASCO president Daniel F. Hayes (University of Michigan Comprehensive Cancer Center, Ann Arbor) is “Making a Difference in Cancer Care WITH YOU,” emphasizing the importance of joint efforts across different professions in the fight against cancer. The increasing amount of research over the past year is reflected in 2150 scientific abstracts that will be presented during oral sessions, clinical science symposia, and poster sessions, with immuno-oncology, precision medicine, and genomics being highlighted the most throughout these sessions.

The prIMElines team has identified 10 key abstracts across various tumor types that have the potential to impact practice in the near future. Please stay tuned throughout June as we bring you comprehensive coverage from the ASCO Annual Meeting.

Breast Cancer

  • Abstract #LBA4—OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) | Plenary Session: Sunday, June 4 from 1.00 PM to 4.00 PM, Hall B1
  • Abstract #LBA500—APHINITY trial (BIG 4-11): A randomized comparison of chemotherapy (C) plus trastuzumab (T) plus placebo (Pla) versus chemotherapy plus trastuzumab (T) plus pertuzumab (P) as adjuvant therapy in patients (pts) with HER2-positive early breast cancer (EBC) | Breast Cancer—Local/Regional/Adjuvant: Monday, June 5 from 9.45 AM to 12.45 PM, Hall D2
  • Abstract 1000—MONARCH 2: Abemaciclib in combination with fulvestrant in patients with HR+/HER2- advanced breast cancer who progressed on endocrine therapy | Breast Cancer—Metastatic: Saturday, June 3 from 1.15 PM to 4.15 PM, Hall D1

Gastrointestinal Cancers

  • Abstract LBA1Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration | Plenary Session: Sunday, June 4 from 1.00 PM to 4.00 PM, Hall B1
  • Abstract 4001Phase III trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC) | Gastrointestinal (Noncolorectal) Cancer: Sunday, June 4 from 8.00 AM to 11.00 AM, Hall D2
  • Abstract 4006Adjuvant capecitabine for biliary tract cancer: The BILCAP randomized study | Gastrointestinal (Noncolorectal) Cancer: Sunday, June 4 from 8.00 AM to 11.00 AM, Hall D2

Genitourinary Cancers

  • Abstract LBA3LATITUDE: A phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer | Plenary Session: Sunday, June 4 from 1.00 PM to 4.00 PM, Hall B1

Lung Cancer

  • Abstract 8500Gefitinib (G) versus vinorelbine+cisplatin (VP) as adjuvant treatment in stage II-IIIA (N1-N2) non-small-cell lung cancer (NSCLC) with EGFR-activating mutation (ADJUVANT): A randomized, Phase III trial (CTONG 1104) | Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers: Monday, June 5 from 8.00 AM to 11.00 AM, Hall B1
  • Abstract LBA9007Dacomitinib versus gefitinib for the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer (ARCHER 1050): A randomized, open-label phase III trial | Lung Cancer—Non-Small Cell Metastatic: Tuesday, June 6 from 9.45 AM to 12.45 PM, Hall D1
  • Abstract LBA9008Alectinib versus crizotinib in treatment-naive advanced ALK-positive non-small cell lung cancer (NSCLC): Primary results of the global phase III ALEX study | Lung Cancer—Non-Small Cell Metastatic: Tuesday, June 6 from 9.45 AM to 12.45 PM, Hall D1

 

 
annual-meeting-preview-prime-oncology